Loading...
•
Mar 31, 2021
Gossamer Bio Q1 2021 Earnings Report
Gossamer Bio announced financial results for the first quarter of 2021 and provided a corporate update.
Key Takeaways
Gossamer Bio reported a net loss of $57.6 million, or $0.78 per share, for the quarter ended March 31, 2021. Cash, cash equivalents and marketable securities totaled $453.3 million as of March 31, 2021.
Seralutinib and GB004 continue to progress through ongoing Phase 2 TORREY and SHIFT-UC clinical trials for Pulmonary Arterial Hypertension (PAH) and Ulcerative Colitis (UC), respectively.
Cash, cash equivalents and marketable securities totaled $453 million as of March 31, 2021
R&D expenses were $41.8 million for the quarter ended March 31, 2021.
Net loss for the quarter ended March 31, 2021, was $57.6 million, or $0.78 per share.